TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05614336

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: Blood serum samples will be collected for analysis of COVID-19 antibody levels. For participants who consent to the optional study, a second blood sample will also be drawn into EDTA tubes (plasma)
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T2
Description: Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T2
Description: Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T2
Description: Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T2
Description: Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T2
Description: Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T2
Description: Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.
Study: NCT05761327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: In the Mediterranean diet; The frequency of consumption of foods such as olive oil, olives, nuts, fish, vegetables and fruits will be given in accordance with the Mediterranean diet pyramid. During the study, it is planned to develop new recipes suitable for the nutritional habits of the individual. The researcher will be able to reach the researcher 7/24 in case of any problem experienced by the individual, and the participant's questions will be answered. Nutrition counseling to this group will be supported by an oral explanation given by the dietitian.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin Supplementation
Description: Participants will take a daily supplement of 1600 mg of curcumin. It is planned that the participants will use 120 capsules of curcumin supplement during the research.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol Supplementation
Description: Participants will take a 500mg resveratrol supplement daily. Participants are planned to use 120 capsules of resveratrol supplement during the study.
Study: NCT05081622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interaction Competencies with Children - for Teachers (ICC-T)
Description: Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.~A one-day ICC-T refresher workshop aiming to refresh and re-emphasize the key aspects of the intervention is implemented about 6 to 12 months after the initial intervention.
Study: NCT04431999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Whole blood transfusion
Description: Severe trauma patients with a life threatening bleeding will be managed with 3 whole blood bags for the 1st and 2nd pack. The later packs will consist of 3 packed red blood cells (PRBCs), 3 plasma units and 1 dose of platelets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fractionated blood products transfusion
Description: Severe trauma patients with a life threatening bleeding will be managed with 3 packed red blood cells (PRBCs), 3 lyophilised plasma units and 1 dose of platelets for the 1st. The 2nd pack will consist of 3 packed red blood cells (PRBCs) and 3 lyophilised plasma units. Then, the later pack will consist of 3 packed red blood cells (PRBCs), 3 plasma units and 1 dose of platelets.
Study: NCT05174637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA018-ADC
Description: FDA018-ADC will be administered via IV infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 \~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 \~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA018-ADC
Description: FDA018-ADC will be administered via IV infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 \~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 \~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
Study: NCT04808362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OMO-103
Description: OMO-103 will be administered intravenously as 30 min infusion once weekly
Study: NCT02399462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar
Description: Agent Dose Route Schedule H.P. Acthar Gel 40 units SC twice weekly\* Weeks 1 and 2~H.P. Acthar Gel 80 units SC twice weekly\* Weeks 3 through 24~H.P. Acthar Gel 80 units SC once weekly\* Weeks 25 through 26~H.P. Acthar Gel 40 units SC once weekly\* Weeks 27 through 28~\*Injections are to be spaced 72-96 hours apart (+/-6 hours).
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T3
Description: Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules
Study: NCT06560866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Just Care for Families
Description: Just Care for Families is a behavioral intervention to address the needs of families involved in or at-risk for involvement with the child welfare system. Just Care involves treatment components, supported by ongoing purposeful engagement: (1) Substance use treatment including contingency management and positive reinforcement, day planning, healthy environments and peer choices, and refusal skills; (2) Mental health treatment including cognitive behavioral therapy, developing healthy coping skills, emotion regulation skills, exposure therapy, and referral for medication management; (3) Parent management training including parenting skills, nurturing and attachment, reinforcement, emotion regulation, supervision, structure, non-harsh discipline, and nutrition; (4) Community building including indigenous and external social supports; (5) Systems navigation; and (6) provision of assistance with basic needs including assistance with housing and employment.
Study: NCT06561269

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multifidus plane block
Description: Using the in-plane technique,The fascial plane between the multifidus muscle and the median sacral crests of S2 and S3, will be injected by bupivacaine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: caudal block
Description: The ultrasound transducer will first be placed transversely at the midline to obtain the transverse view of sacral hiatus. At this level, the ultrasound transducer is rotated 90 degrees to obtain the longitudinal view of sacral hiatus. The block needle is inserted using the in-plane technique.
Study: NCT05542056

Intervention type: OTHER
Intervention: Data and biosample collection
Description: Collection of spot urine, blood sampling, vital parameters, body weight, medical history, patient questionnaires, drinking protocol, drug diary at at Visit 1 (before thiazide initiation), at Optional 2 hours-challenge, at Visit 2 (4 weeks after thiazide initiation), at Visit 2.1 (4 weeks after dose change), at Visit 3 (3-months after thiazide initiation)
Study: NCT05206851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage and Hot Pack
Description: Application of hot pack for 20 minutes at low back in sitting, and then the participant will perform deep diaphragmatic breathing for 10 minutes, following these steps:~1. Sitting in comfortable position~2. One hand is placed over chest and other on abdomen.~3. Inhale deep through the nose.~4. Exhale through mouth, completely, counting back from 4 to 1. Application rotary or stationary circle over low back in side lying position, in pregnant females. A session of 20-30 minutes of Manual Lymphatic Drainage will be given biweekly.~And at the end of Manual Lymphatic Drainage application, deep breathing for 10 minutes will be performed again.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hot Pack
Description: Hot pack will be applied at low back, for 20 minutes as home based protocol.
Study: NCT05725499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biostim-5 transcutaneous spinal stimulator
Description: Transcutaneous stimulation of the spinal cord. Mapping will be performed to determine sites for optimal modulation of blood pressure. During each mapping day, with participants in a supine or seated position, electrodes will be placed on the midline of one of the following spinous processes: C5/6, T7/8, T11/12, L1/2 and S1/2. Stimulation intensity will start at 5 mA and gradually increased in 5 mA increments up to 100 mA. The frequency will be 2 or 30 Hz. Profiles will be established to guide selection of optimal site locations for blood pressure modulation. The profile chosen will be used during training and testing.~During testing, stimulation will be applied using the selected profile in order to normalize SBP to the range of 110-120 mmHg and stabilize it within this range during a 30-min tilt test.~On each session during the 2-week training-period, stimulation will be applied for 30 minutes using the selected profile, while the participant remains in a seated position.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tilt-table orthostatic stress testing
Description: While lying supine, participants will be strapped to a Hi-Low tilt-table bed. The bed will gradually be tilted to a 70 degrees tilt, during which time continuous hemodynamic measures will be recorded. This position will be maintained for 30 minutes.~During some of the sessions, the tilt test will be accompanied by spinal stimulation.
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T3
Description: Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules
Study: NCT05545306

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Description: +200% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Study: NCT03939364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBS-101
Description: Isotretinoin Oral-Adhesive Film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBS-101
Description: Isotretinoin Oral-Adhesive Film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBS-101
Description: Isotretinoin Oral-Adhesive Film

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05545306

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Description: +200% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Description: +200% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T3
Description: Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T3
Description: Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules
Study: NCT06356636

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial Inclusion Improves Sanitation and Health
Description: This innovative model engages transformative partnerships which include four key stakeholders (communities, communities, governments, entrepreneurs, and financiers) to improve sanitation services and supply value chains. The work is two-sided: to create demand for improved sanitation facilities in communities while facilitating microcredit access for people and sanitation businesses on the supply side.
Study: NCT06271005

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NeuroTears
Description: Over-the-counter supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo pill
Study: NCT05059028

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin massage AND music therapy
Description: Oxytocin massage: It is a massage that will accelerate the work of the parasympathetic nerves in order to transmit the oxytocin production stimulus to the posterior lobe of the brain. Massage the scapula from the cervical 7th to the 5th-6th spine, spinal (vertebral), 1-2 cm around the spine, both thumbs up and then 2-3 times down, in a small circular clockwise, downward and upward movements. It is a form of massage by pressing hard.~Music intervention: In order to decide on the type of music to be played to the mothers during breastfeeding, three samples (Pentatonic, Büzürk makam and classical music) selected by the researcher will be asked to the postpartum mother, and the music preferred by the mothers will be determined. It will be ensured that mothers listen to the music determined 5 minutes before the breastfeeding session for 7 days and continue breastfeeding while the same music is playing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin massage AND music therapy
Description: Oxytocin massage: It is a massage that will accelerate the work of the parasympathetic nerves in order to transmit the oxytocin production stimulus to the posterior lobe of the brain. Massage the scapula from the cervical 7th to the 5th-6th spine, spinal (vertebral), 1-2 cm around the spine, both thumbs up and then 2-3 times down, in a small circular clockwise, downward and upward movements. It is a form of massage by pressing hard.~Music intervention: In order to decide on the type of music to be played to the mothers during breastfeeding, three samples (Pentatonic, Büzürk makam and classical music) selected by the researcher will be asked to the postpartum mother, and the music preferred by the mothers will be determined. It will be ensured that mothers listen to the music determined 5 minutes before the breastfeeding session for 7 days and continue breastfeeding while the same music is playing.
Study: NCT05250960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCD
Description: Patient will receive 1L of LR and have SCDs applied 15 minutes before epidural placement and will be removed 1 hour after epidural placement
Study: NCT06562088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM1002 and rifampicin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM1002 and itraconazole
Description: Administered orally
Study: NCT04892953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Consolidation Therapy
Description: Undergo LCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Consolidation Therapy
Description: Undergo LCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Complete questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Complete questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT05387109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: penpulimab combined with anlotinib
Description: penpulimab: fixed dose of 200 mg, administered on the first day of each cycle, repeated every 3 weeks; Anlotinib: 12 mg, administered on days 1-14, orally once a day, about half an hour before breakfast (the daily dose should be as much as possible), taken with warm water, and repeated every 3 weeks
Study: NCT05325515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional alendronate
Description: Conventional alendronate 70mg weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Effervescent and buffered alendronate
Description: Effervescent and buffered alendronate 70mg weekly
Study: NCT05545306

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Description: +200% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Description: +200% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Description: +200% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Description: +200% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T3
Description: Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T3
Description: Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T3
Description: Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T3
Description: Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T3
Description: Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T3
Description: Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T3
Description: Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T3
Description: Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T3
Description: Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T3
Description: Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T3
Description: Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T3
Description: Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules
Study: NCT05545306

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Description: +200% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Description: +200% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Description: +200% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fasting
Description: Fasting for at least 24 hours

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fasting
Description: Fasting for at least 24 hours

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fasting
Description: Fasting for at least 24 hours
Study: NCT04679376

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered daily orally in tablet or capsule form, contains no active medicine